Evidence map›Paper›PMID 34469441›Full record

ArticlePloS one2021

Real-world evaluation of costs of illness for pneumonia in adult patients in Dubai-A claims database study.

Sara Ahmad Mohammad Al Dallal, Mohamed Farghaly, Ahmed Ghorab, Mostafa Elaassar, Hammam Haridy, Nancy Awad, Badarinath Chickballapur Ramachandrachar, Ashok Natarajan

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Hospital Cost Components and Predictors inTropical medicine and infectious disease · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara Ahmad Mohammad Al DallalHealth Economics & Insurance Policies Department, Dubai Health Authority, Dubai, UAE.ORCID 0000-0001-7623-5402
Mohamed FarghalyHealth Economics & Insurance Policies Department, Dubai Health Authority, Dubai, UAE.
Ahmed GhorabHealth & Value and Patient Outcomes, Pfizer, Dubai, UAE.
Mostafa ElaassarVaccines, Medical & Scientific Affairs, Pfizer, Dubai, UAE.
Hammam HaridyVaccines, Medical & Scientific Affairs, Pfizer, Dubai, UAE.
Nancy AwadReal World Evidence, IQVIA, Dubai, UAE.
Badarinath Chickballapur RamachandracharReal World Evidence, IQVIA, Dubai, UAE.
Ashok NatarajanReal World Evidence, IQVIA, Dubai, UAE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPneumonia is a significant cause of morbidity and mortality among adults globally. This retrospective cohort analysis assessed the pneumonia burden and related healthcare resource utilization and costs in the at-risk (low, medium, and high-risk) adult patients in Dubai, United Arab Emirates (UAE).

methodsThe claims data from January 1, 2014 to June 30, 2019 were extracted from the Dubai Real-World Claims Database for patients, aged ≥18 year, having at least 1 pneumonia claim. Data for the inpatient, outpatient and emergency visits were assessed for 12-months, before (pre-index) and after (follow-up) a pneumonia episode. Healthcare costs were calculated based on dollar value of 2020.

resultsTotal 48,562 records of eligible patients were analyzed (mean age = 39.9 years; low [62.1%], medium [36.2%] and high [1.7%] risk cohorts). Mean all-cause healthcare costs were approximately >45% higher in the follow-up period (1,947 USD/patient) versus pre-index period (1,327 USD/patient). During follow-up period, the mean annual pneumonia incidence rate was 1.3 episodes, with a similar pattern across all cohorts. Overall, mean claims and costs (USD) per patient (all-cause) were highest in the high-risk cohort in the follow-up period (claims: overall, 11.6; high-risk, 22.0; medium-risk, 13.9; low-risk, 9.9; costs: high-risk, 14,184; medium-risk, 2,240; low-risk, 1,388). Similarly, the mean pneumonia-related costs (USD) per patient were highest for the high-risk cohort (overall: 1,305; high-risk, 10,207; medium-risk, 1,283; low-risk, 882), however, the claims were similar across cohorts (claims/patient: overall: 2.0; high-risk, 1.9; medium-risk, 2.2; low-risk, 1.9). Most all-cause and pneumonia-related costs were due to inpatient visits (4,901 and 4,818 USD respectively), while outpatient (1,232 and 166 USD respectively) and emergency visits (347 and 206 USD respectively) contributed significantly lesser.

conclusionsPneumonia imposes a significant healthcare burden in the UAE, especially in the high-risk patients with severe comorbidities. These findings would guide clinicians and policy makers to make informed decisions.

Indexed as

Cost of IllnessAdministrative Claims, HealthcareAdolescentAdultDatabases, FactualFemaleFollow-Up StudiesHealth Care CostsHumansMaleMiddle AgedPatient Acceptance of Health CarePneumoniaRetrospective StudiesUnited Arab EmiratesYoung Adult

Identifiers

PMID34469441
PMCPMC8409655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.